Esophageal Stents Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Esophageal Stents Market Trends and Insights

Rising Incidence Of Esophageal Cancer And Malignant Dysphagia

Esophageal cancer remains the strongest volume driver in the esophageal stents market, with 511,054 new cases and 445,391 deaths recorded globally in 2022. Global annual cases are projected to rise to 922,638 by 2050, which supports a long runway for palliative intervention demand. China represented 43.8% of the worldwide incidence in 2022, with 224,012 new diagnoses, which creates a very large regional treatment base for dysphagia management. The same projection work showed large future increases in East Asia and high human development index countries, so the disease burden is broadening across both mature and developing systems. Malawi and Uganda already reported age-standardized incidence rates of 17.9 and 13.2 per 100,000, yet access to advanced endoscopic care in many African settings remains limited. As oncology access improves in underserved regions, the esophageal stents market should benefit from both newly treated patients and higher procedural throughput.

Expanding Use Of Minimally Invasive Endoscopic Therapy

The shift from open surgery toward endoscopic management is changing how the esophageal stents market is used in routine care. Endoscopic stent placement can allow oral intake within 1 to 2 days and can reduce hospitalization time compared with surgical alternatives.^{[1]“Stents and Emerging Alternatives in Upper Gastrointestinal Diseases,”}That treatment pattern fits well with payer and provider efforts to limit inpatient use and shorten recovery time. Smaller delivery systems are also making placement more feasible in tight spaces and less dependent on highly specialized operating environments. This is helping more outpatient endoscopy units consider procedures that were once concentrated in large hospitals. As training expectations become more consistent, the esophageal stents market benefits from a broader pool of endoscopists who can perform placements safely and efficiently.

Product Innovation In Covered, Anti-Migration, And Biodegradable Designs

Product design remains a major competitive lever in the esophageal stents market. A 2025 multicenter study found that fully covered self-expanding metal stents fixed with clips that used anchor prongs achieved a 43% relative risk reduction in migration compared with unfixed controls. That result matters because migration rates in benign stricture settings have historically ranged from 4% to 54%, which keeps follow-up burden high for both clinicians and patients. ELLA-CS released updated HV Stent Plus and Flexella Plus biodegradable stents with a 20 mm diameter option and a 22F slim delivery system, which expanded eligibility in tighter anatomical strictures.^{[2]“New Version of the HV Stent Plus and Flexella Plus Released,”} These refinements improve fit across a wider case mix and make advanced designs easier to use in difficult anatomy. As fixation and delivery continue to improve together, the esophageal stents market gains from better procedure confidence as well as a broader set of treatable patients.

Broader Adoption In Palliative Care Pathways

Palliative oncology remains a steady demand base for the esophageal stents market. A 2025 retrospective study from Cambridge University Hospitals found that self-expanding metal stents provided meaningful symptom relief in late-stage esophageal cancer.^{[3]“Clinical Characteristics, Complications, and Post-stent Survival in Patients Undergoing Palliative Oesophageal Stenting, A Retrospective Study,”} This supports the role of stenting as a quality-of-life intervention when curative treatment is not possible. Care pathways in the United States, the United Kingdom, and Germany are also treating stenting more as a standard response for inoperable malignant dysphagia, which makes procedural demand more predictable. Multidisciplinary teams are increasingly aligning stent timing with radiotherapy schedules to maintain swallowing function during treatment. This pattern supports the esophageal stents market because it favors suppliers that can offer reliable covered stents and dependable clinical support across oncology centers.

Stent-Related Complications And Re-Intervention Risk

Complications still limit how far the esophageal stents market can expand in benign disease. A 2024 multicenter study reported migration rates of 22.8% for conventional fully covered self-expanding metal stents and 26.6% for segmented fully covered self-expanding metal stents.^{[4]“Safety and Efficacy of Conventional Compared to Segmented Esophageal Fully Covered Self-Expanding Metal Stents, A Retrospective Multicenter Case-Control Study,”} Those rates sit within a broader published range of 4% to 54%, which shows that current engineering approaches have not fully resolved the problem. A 2025 systematic review and meta-analysis of biodegradable stents found hyperplastic tissue reactions in 16.4% of patients, with high heterogeneity across studies. Anchoring tools, such as through-the-scope suturing, may improve stability, but they also add equipment needs and operator skill requirements. This keeps many complex cases concentrated in tertiary centers and slows wider adoption across community settings in the esophageal stents market.

Limited Reimbursement And Budget Pressure In Price-Sensitive Markets

Reimbursement gaps continue to hold back the esophageal stents market in price-sensitive healthcare systems. High-income countries support more consistent therapeutic endoscopy volumes because payment pathways are clearer and hospital procurement budgets are stronger. In contrast, many systems across South Asia, Southeast Asia, Latin America, and sub-Saharan Africa still lack dependable procedure-level coverage for palliative stenting. Hospitals in those settings often need to balance device costs against limited oncology budgets, even when patient need is clear. This also creates room for lower-priced local products with uneven clinical validation to enter the supply base. Until payer support improves, the esophageal stents market will continue to show a gap between underlying disease burden and realized procedural volume.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: SEMS Lead While Biodegradable Stents Expand The Treatable Pool

Self-expanding metal stents accounted for 73.48% of the esophageal stents market size in 2025. Their lead reflects long clinical use in malignant dysphagia, broad physician familiarity, and the availability of covered, partially covered, and uncovered formats for different stricture types. The esophageal stents market continues to lean heavily on this category because product progress is coming through steady refinement rather than full technology replacement. Self-expanding plastic stents now occupy a narrower role because larger catheter profiles, higher migration risk, and greater handling complexity have reduced their appeal in malignant use.

Biodegradable stents are projected to grow at 5.89% CAGR from 2026 to 2031 in the esophageal stents industry. Their main advantage is that they can degrade within 3 to 4 months and avoid a retrieval endoscopy in selected benign stricture cases. That makes growth in the esophageal stents market more additive than disruptive, because some patients who avoided stenting may accept a biodegradable option. A 2024 review found that biodegradable stents had not shown clear statistical superiority over self-expanding metal or plastic stents in meta-analyses, yet sequential placement strategies are receiving more attention for extending dysphagia-free intervals.

By Material: Nitinol Holds The Core While Polymer Use Broadens

Nitinol held 68.24% of material revenue in 2025 within the esophageal stents market. Its shape memory, superelastic behavior, and stable radial force make it the standard material for devices that must function through repeated esophageal motion. This has steadily reduced the role of stainless steel in modern esophageal stent design. Established suppliers also benefit because validated material sourcing and manufacturing experience matter in regulated implantable devices.

Plastic and polymer materials are projected to grow at 6.32% CAGR through 2031 in the esophageal stents market. Part of that rise comes from cost pressure in outpatient procurement, while another part comes from faster work on biodegradable platforms. Polydioxanone and PLLA are central to this shift because they support temporary scaffolds that do not need later removal in selected use cases. A 2025 Biomaterials study described a degradable biomimetic stent with hydrogel and a directional TGF-loaded nanofiber membrane for esophageal fistula treatment, which shows how polymer research is moving beyond passive lumen support.

By Application: Malignant Cases Anchor Demand While Fistula Care Grows Faster

Malignant indications accounted for 76.51% of the esophageal stents market size in 2025. Dysphagia palliation in inoperable esophageal, gastric, and lung cancers remains the most standardized use case and the biggest source of predictable procedure volumes. The esophageal stents market still draws most of its commercial base from malignant care because referral patterns are established and treatment pathways are clearer than they are in many benign settings. A 2025 single-center retrospective study reported that 64% of esophageal stent placements were for malignant causes and 36% were for benign causes, with self-expanding metal stents used in all patients.

Tracheoesophageal fistulas are projected to grow at 7.25% CAGR through 2031 and represent the fastest-growing application in the esophageal stents market. Growth is being supported by the wider use of dual esophageal and airway stenting in patients who are not good surgical candidates. A 2024 study found that stent implantation reduced pneumonia incidence from 83.5% at baseline to 33.5% at 1 month in malignant tracheoesophageal fistula care. A 2025 review also reported better fistula closure and quality-of-life outcomes with endoscopic management, which supports continued expansion in high-acuity oncology centers.

By End User: Hospitals Stay Largest While Endoscopy Centers Gain Speed

Hospitals held 62.31% of the esophageal stents market share in 2025. They remain the leading care setting because complex gastrointestinal endoscopy often requires imaging support, oncology coordination, and access to acute care backup. The esophageal stents market has long been centered in hospital departments, especially for difficult malignant strictures and medically fragile patients. Specialty clinics and ambulatory settings still play a role in selected benign cases and referral-based tertiary programs.

Endoscopy centers are projected to grow at 8.41% CAGR through 2031 and are the fastest-growing end-user group in the esophageal stents market. Smaller delivery systems are making placement more feasible in outpatient environments, especially when cases do not require the resources of a full hospital department. This shift is broadening the site-of-care mix in the esophageal stents market and is increasing demand for products that are easier to stock, handle, and deploy. Manufacturers that tailor packaging and delivery features to routine endoscopy workflows should benefit as more procedures move into these settings.

Geography Analysis

North America held 37.68% of the esophageal stents market size in 2025. The United States accounted for most of that base because accredited endoscopy capacity, therapeutic expertise, and established reimbursement pathways supported high procedure throughput. Canada and Mexico added smaller contributions, with growth tied to oncology protocol development in Canada and private hospital investment in Mexico. The esophageal stents market in North America is also an important launch region for advanced covered stents because large health systems can adopt refinements faster than many other regions.

Asia-Pacific is forecast to expand at 8.93% CAGR through 2031 and is the fastest-growing region in the esophageal stents market. China represented 43.8% of global esophageal cancer incidence in 2022, which gives the region a very deep underlying treatment pool. Expansion of endoscopy infrastructure in China is opening more procedural capacity in second-tier and third-tier cities, which should support future placement volumes. Japan and South Korea remain early adopters of specialized stent platforms, and strong endoscopic practice patterns support quicker uptake of new designs. India is still smaller, but it is gaining traction as private tertiary hospitals expand advanced gastroenterology services.

Europe holds a steady position in the esophageal stents market, with Germany, the United Kingdom, France, and Italy supported by strong procedural standards and aging patient pools. South America is growing more gradually because public budget limits continue to weigh on adoption, even though private hospitals are adopting more advanced endoscopy protocols. The Middle East is seeing selective investment in oncology infrastructure, especially in GCC systems that are building advanced care capacity. Sub-Saharan Africa has some of the highest disease incidence, including 17.9 cases per 100,000 in Malawi, but much of that need remains commercially underserved because endoscopy access and reimbursement are still limited.